C. D. da Veiga

Number needed to treat analysis applied to pembrolizumab plus chemotherapy for first-line treatment of non-squamous non-small cell lung cancer

C. Baldotto, L. Paladini, C. D. da Veiga, 2021, Journal of medical economics.

Reducing meat consumption: insights from a bibliometric analysis and future scopes

Germano Glufke Reis, C. P. da Veiga, L. Pascuci, 2022, Future Foods.

Social Media Analysis to Understand the Expected Benefits by Plant-Based Meat Alternatives Consumers

Germano Glufke Reis, Z. Su, C. P. da Veiga, 2021, Foods.

Concern over cost of and access to cancer treatments: A meta-narrative review of nivolumab and pembrolizumab studies.

Claudimar Pereira da Veiga, C. P. da Veiga, Cássia Rita Pereira da Veiga, 2018, Critical reviews in oncology/hematology.

Pembrolizumab plus axitinib and nivolumab plus ipilimumab as first-line treatments of advanced intermediate- or poor-risk renal-cell carcinoma: a number needed to treat analysis from the Brazilian private perspective

D. Jardim, C. D. da Veiga, L. Chabrol Haas, 2021, Journal of medical economics.

Cutaneous melanoma: cost of illness under Brazilian health system perspectives

C. P. da Veiga, A. C. de Melo, A. Wainstein, 2021, BMC Health Services Research.

After-Sales Attributes in E-Commerce: A Systematic Literature Review and Future Research Agenda

C. Veiga, C. P. da Veiga, C. D. da Veiga, 2023, J. Theor. Appl. Electron. Commer. Res..

Attitude and Purchase Intention to Generic Drugs

Claudimar Pereira da Veiga, C. D. da Veiga, W. V. da Silva, 2021, International journal of environmental research and public health.

Immune checkpoint inhibitors for the treatment of non-small cell lung cancer: the regulatory journey in Brazil.

A. P. Drummond-Lage, C. D. da Veiga, C. D. da Veiga, 2023, Critical reviews in oncology/hematology.